Trial Profile

PHASE II TRIAL OF SUNITINIB IN PATIENTS WITH TYPE B3 THYMOMA OR THYMIC CARCINOMA IN SECOND AND FURTHER LINES (STYLE Trial)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sunitinib (Primary)
Indications Malignant thymoma; Thymic epithelial tumour; Thymoma
Focus Therapeutic Use
Acronyms Style; Style Trial

Most Recent Events

22 Apr 2023 Results (n=44) published in the Journal of Thoracic Oncology
09 Aug 2022 Results (n=44) presented at the 2022 World Conference on Lung Cancer
08 Jun 2021 Planned End Date changed from 2 Mar 2021 to 31 May 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com